Susannah J. Patey

Interactions of Multiple Heparin Binding Growth Factors with Neuropilin-1 and Potentiation of the Activity of Fibroblast Growth Factor-2

The hypothesis that neuropilin-1 (Npn-1) may interact with heparin-binding proteins other than vascular endothelial growth factor has been tested using an optical biosensor-based binding assay. The results show that fibroblast growth factor (FGF) 1, 2, 4, and 7, FGF receptor 1, hepatocyte growth factor/scatter factor (HGF/SF), FGF-binding protein, normal protease sensitive form of prion protein, antithrombin III, and Npn-1 itself are all able to interact with Npn-1 immobilized on the sensor surface. FGF-2, FGF-4, and HGF/SF are also shown to interact with Npn-1 in a solution assay. Moreover, these protein-protein interactions are dependent on the ionic strength of the medium and are inhibited by heparin, and the kinetics of binding of FGF-2, FGF-4 and HGF/SF to Npn-1 are characterized by fast association rate constants (270,000–1,600,000 m–1 s–1). These results suggest that Npn-1 possesses a “heparin” mimetic site that is able to interact at least in part through ionic bonding with the heparin binding site on many of the proteins studied. Npn-1 was also found to potentiate the growth stimulatory activity of FGF-2 on human umbilical vein endothelial cells, indicating that Npn-1 may not just bind but also regulate the activity of heparin-binding proteins.

Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.

Background: Cleavage of β-amyloid precursor protein (APP) by the protease β-secretase (BACE1) is a key step in β-amyloid peptide processing. We have described a novel role for heparan sulphate polysaccharides in Alzheimer’s disease pathology as naturally occurring inhibitors of β-secretase, suggesting new avenues for discovery of novel drugs for Alzheimer’s disease based on heparins. Objective: To evaluate engineered heparin analogues as novel β-secretase inhibitors in vitro, including modifications to increase bioavailability. Methods: We tested a number of selectively desulphated and chemically modified heparins for their ability to inhibit BACE1 and other proteases in vitro using APP fluorescent resonance energy transfer peptide substrates Results: Several lead compounds have been identified that are effective β-secretase inhibitors, but have negligible activity as anticoagulants or as inhibitors of other aspartyl proteases structurally related to β-secretase. In addition, the compounds studied also give some insight into the structural interaction between β-secretase and heparin, indicating that the structure of the polysaccharide is much more important than charge. Conclusion: We have demonstrated that modifications to increase bioavailability of chemically modified heparins have little effect on their efficacy as β-secretase inhibitors. Therefore, these heparins show promise for development as a novel class of pharmaceuticals that target the underlying pathology of Alzheimer’s disease. We have also found further evidence that it is the structure of the polysaccharide that is important for the interaction with β-secretase, not simply the level of sulphation or charge.

Novel heparan sulphate analogues: inhibition of β-secretase cleavage of amyloid precursor protein

The role of HS (heparan sulphate) in the pathology of AD (Alzheimers disease) is multifaceted. HS and other glycosaminoglycans have been widely reported to be associated with neuritic plaques. HS has also been shown to promote the aggregation of Abeta (amyloid beta-peptide), the proteinaceous component of neuritic plaques. Recently, we described a novel and contrasting role for HS in the pathology of AD: HS can inhibit the formation of Abeta, by directly interacting with the protease BACE1 (beta-site amyloid precursor protein cleaving enzyme 1; beta-secretase 1), that cleaves the amyloid precursor protein and is the rate limiting step in the generation of Abeta. Here, we review the current roles of HS and the potential for HS-derivatives in the treatment of AD.

Highly diverse heparan sulfate analogue libraries: a novel resource for bioactivity screening of proteins

Introduction  Fibroblast growth factors (FGFs) are a multipotent family of growth factors that are important for many biological processes, including development and wound healing. Normal, protease sensitive, prion protein (PrPC) can be converted to the protease resistant, infectious, form (PrPSc) believed to be associated with the pathogenesis of transmissible spongiform encephalopathies. FGFs signal through a family of tyrosine kinase receptors, the FGF receptors (FGFR) with the aid of heparan sulfate (HS), while the role of HS in the biology of PrPC is currently unknown, although depleting cells of HS can prevent production of PrPSc. HS, or its more highly sulfated relation heparin, can exert both positive and negative regulatory activities on a particular FGF‐FGFR combination. The nature of this regulation is determined by the structure of the HS that binds to the proteins. This structure is at least partially determined by the presence of particular sulfate groups along the sugar backbone. Identification of specific sulfate groups that can regulate the activity of proteins has been a long‐term goal in the field. Previously, heparins that had been completely lacking sulfates at specific positions were used to determine the binding and activity requirements for a particular protein. However, this may not necessarily allow for a full examination of the regulatory properties of HS. Here, we present a heparan sulfate analogue library produced by the partial, combinatorial desulfation of heparin. This library was the used to examine the structural properties of heparin required for FGF‐1 signalling through FGFR2c as well as the interactions of HS with PrPC.